Accessibility Menu

Exelixis(FRA) EX9

Market Cap€11.63BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)+142%
5 Year+233%
1 Year+62%
1 Month+3%
€46.43
-1.07%
-0.50Today
Exelixis last closing stock price
MetricPriceDate
Last closeEUR 54.642026-08-31
Exelixis stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.16%EUR 54.552026-08-24
1 month+3.04%EUR 53.032026-07-31
3 month+62.04%EUR 33.722025-03-14
Year to date+62.04%EUR 33.722025-03-14
1 year+62.04%EUR 33.722025-03-14
3 year+159.08%EUR 21.092023-09-01
5 year+232.56%EUR 16.432021-09-01
Since inception+141.91%EUR 19.402000-04-28

Exelixis Financials at a Glance

Market Cap

€11.63BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€2.09K

Net Income (TTM)

€738.01

EPS (TTM)

€2.73

P/E Ratio

17.19

Dividend

€0.00

Beta (Volatility)

-0.01 (Low)

Price

€46.43

Volume

0

Open

€46.43

Previous Close

€46.43

Daily Range

€46.43 - €46.43

52-Week Range

€29.41 - €49.80

Estimated Earnings Date

N/A

EX9 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Exelixis

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Industry

Biotechnology

Employees

1,077

CEO

Michael M. Morrissey, PhD

EX9 Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

44.13%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

5.82%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

€11.63BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

247.78M

Volume

0

Avg. Volume

134.121

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Exelixis Performance Analysis

Exelixis annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 1,532,922,33226.3%
20232023-12-31EUR 1,692,888,34110.4%
20242024-12-31EUR 2,004,917,75218.4%
20252025-12-31EUR 2,055,795,9682.5%
Exelixis annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 0.53-11.9%
20232023-12-31EUR 0.6011.9%
20242024-12-31EUR 1.63172.2%
20252025-12-31EUR 2.4651.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€540.71

+1.1%

Gross Profit

€522.94

+1.1%

Gross Margin

96.71%

+1.0%

Market Cap

€11.63BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

€11.23

N/A

Employees

1,077

N/A

Net Income

€182.38

+1.1%

EBITDA

€219.66

+1.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€342.42

+33.6%

Total Debt

€145.13

+0.9%

Accounts Receivable

€281.83

+1.1%

Inventory

€25.13

+1.3%

Long Term Debt

€145.13

+0.9%

Short Term Debt

€0.00

N/A

Return on Assets

33.07%

+1.5%

Return on Invested Capital

16.15%

+1.6%

Free Cash Flow

€260.14

+9.8%

Operating Cash Flow

€266.01

+9.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About EX9

What is the current price of Exelixis?

Exelixis is trading at €46.43 per share.

What is the 52-week range for Exelixis?

Over the past 52 weeks, Exelixis has traded between €29.41 and €49.80.

How much debt does Exelixis have?

As of the most recent reporting period, Exelixis reported total debt of €145.13M.

How much cash does Exelixis have on hand?

Exelixis reported €197.29M in cash and cash equivalents in its most recent financial results.

What is Exelixis’s dividend yield?

Exelixis does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.